<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543565</url>
  </required_header>
  <id_info>
    <org_study_id>BOJI201939F</org_study_id>
    <nct_id>NCT04543565</nct_id>
  </id_info>
  <brief_title>Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study</brief_title>
  <official_title>Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Multi-center, Double-Blind, Randomized, Positive Control, Phase3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xi'an Xintong Pharmaceutical Research Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xi'an Xintong Pharmaceutical Research Co.,Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in&#xD;
      chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at&#xD;
      a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open.&#xD;
      The interim analysis will be conducted when all subject completed the first 48-week&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this is a randomized, double-blind, positive drug parallel control, multicenter, phase 3&#xD;
      study .Eligible HBeAg-positive or HBeAg-negative chronic hepatitis B patients will be&#xD;
      stratified by historical antiviral treatment (untreated or treated) at the time of screening,&#xD;
      and then randomly assigned to Pradefovir mesylate tablet group or tenofovir disoproxil&#xD;
      fumarate tablet group at a ratio of 2:1. The proportion of subject with compensatory stage of&#xD;
      cirrhosis is no more than 20 percentage. Patients will receive a total of 144 weeks of&#xD;
      antiviral treatments, and after 96 weeks of double-blind treatment, all subjects will switch&#xD;
      to open mesylate Pradefovir tablets for additional 48 weeks. The first 48 weeks are the core&#xD;
      period and the followed 96 weeks are the extension period. Statistical analysis was conducted&#xD;
      on the efficacy and safety of the whole trial. (After the completion of 48-week visit of the&#xD;
      last one subject, the interim analysis will be conducted. The analysts will be unblinded,&#xD;
      while the remaining participants will still be blind.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV viral suppression</measure>
    <time_frame>After 48-week therapy</time_frame>
    <description>proportion of patients with hepatitis B virus(HBV) -DNA undetectable(&lt;29IU/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV viral suppression</measure>
    <time_frame>After therapy of 4, 8, 12, 24, 36, 72, 96, 144 weeks</time_frame>
    <description>proportion of patients with hepatitis B virus(HBV) -DNA undetectable(&lt;29IU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV viral suppression</measure>
    <time_frame>After therapy of 4, 8, 12, 24, 48, 36, 72, 96, 144 weeks</time_frame>
    <description>proportion of patients with hepatitis B virus(HBV) -DNA undetectable(&lt;20IU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reduction of HBV DNA load</measure>
    <time_frame>at week 4, 8, 12, 24, 36, 48, 72, 96, 144</time_frame>
    <description>the change of HBV DNA load from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>After therapy of 4, 8, 12, 24, 48, 36, 72, 96, 144 weeks</time_frame>
    <description>proportion of patients with ALT normalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Trial group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject in this group will receive Pradefovir mesylate tablet and the placebo of tenofovir disoproxil fumarate tablet, once daily for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subject in this group will receive tenofovir disoproxil fumarate tablet and the placebo of Pradefovir mesylate tablet, once daily for 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Trial group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 to 65 years old, male or female.&#xD;
&#xD;
          -  Meets the diagnosis and treatment standards of chronic hepatitis B( HBsAg or HBV DNA&#xD;
             positive over 6 months, or diagnosed by liver biopsy.&#xD;
&#xD;
          -  For HBeAg positive, HBV DNA equal or over 20000 IU/ml; for HBeAg negative ,HBV DNA&#xD;
             equal or over 2000 IU/ml.&#xD;
&#xD;
          -  ALT level between 1.2 ULN to 10 UNL.&#xD;
&#xD;
          -  Treatment naive or experienced when any nucleos(t)ide analogs or interferons stopped&#xD;
             over 6 months.&#xD;
&#xD;
          -  Use of effective contraceptive measures if procreative potential exists.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to study drug,metabolite product or excipient.&#xD;
&#xD;
          -  Evidence of hepatic decompensation such as Child-Pugh B or C, with previous&#xD;
             gastroesophageal variceal haemorrhage, hepatic encephalopathy, ascites&#xD;
&#xD;
          -  Suspected or confirmed hepatocellular carcinoma, or AFP&gt;50μg/L.&#xD;
&#xD;
          -  Other liver diseases (such as Chronic alcoholic hepatitis, drug-induced hepatitis,&#xD;
             autoimmune liver disease).&#xD;
&#xD;
          -  Resistant to antiviral drugs (adefovir or tenofovir).&#xD;
&#xD;
          -  Concommitant disease of severe heart, blood, respiratory and central nervous system&#xD;
             diseases.&#xD;
&#xD;
          -  Chronic kidney diseases, or Ccr&lt;60ml/min at screening.&#xD;
&#xD;
          -  Abnormal hematological and biochemical parameters at screening: White blood cell count&#xD;
             less than 3.0×109/L，or neutrophil count less than 1.5×109/L，or platelet count less&#xD;
             than 80×109/L，or total bilirubin more than 2ULN，or the prolong of PT more than 3s.&#xD;
&#xD;
          -  Positive-HCV or positive-HIV.&#xD;
&#xD;
          -  Severe bone disease (such as osteomalacia, chronic osteomyelitis, osteogenesis&#xD;
             imperfecta, rickets) or multiple fractures.&#xD;
&#xD;
          -  History of pancreatitis or malignancy within 5 years (excluding cervical epithelial&#xD;
             carcinoma, squamous epithelial carcinoma, or basal cell carcinoma of the skin that was&#xD;
             clinically cured within 5 years of diagnosis).&#xD;
&#xD;
          -  Plan to receive or have already had an organ transplant.&#xD;
&#xD;
          -  Subject with disabilities as prescribed by law (blindness, deafness, deafness,&#xD;
             deafness, mental disorders, etc.).&#xD;
&#xD;
          -  History of alcohol or drug abuse within the last 1 year.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Participated in any clinical trial or taken any IMP (investigational medical product)&#xD;
             within 3 months prior to the trial.&#xD;
&#xD;
          -  Other cases that could not be enrolled in the judgement of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>daidi Wang</last_name>
    <phone>+86 029 68790358</phone>
    <email>wangdd@xtyw.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqi Niu, Dr.</last_name>
      <phone>13756661205</phone>
      <email>junqiniu@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Pradefovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

